Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apogossypol is a semi-synthetic small-molecule BH3 mimic derived from gossypol, a natural polyphenol found in cottonseed. It was specifically engineered to lack the reactive aldehyde groups present in gossypol, which are associated with off-target toxicity, while retaining potent inhibitory activity against anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-XL, and Mcl-1. By binding to the hydrophobic grooves of these proteins, apogossypol prevents them from sequestering pro-apoptotic proteins, thereby triggering the intrinsic apoptotic pathway in cancer cells. Preclinical research has demonstrated its efficacy in inhibiting the growth and proliferation of various malignancies, particularly prostate cancer and hematologic tumors, with a significantly improved safety profile compared to its parent compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on apogossypol.